Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma

Mireille M. Hermans, Corstiaan C. Breugem, Renske Schappin, Emma Jonge Poerink, Elodie J. Mendels, Aviël Ragamin, Johannes M.P.J. Breur, Hester R. Langeveld, Martine F. Raphael, Peter C.J. De Laat, Saskia N. De Wildt, André B. Rietman, Suzanne G.M.A. Pasmans, Marlies De Graaf

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol. Different types of beta-blockers may result in different long-term aesthetic outcomes. This study evaluated the difference in long-term aesthetic outcomes between infantile haemangiomas treated with either propranolol or atenolol, including the perspective of physicians, parents, and children. Children, aged ≥6 years, treated with propranolol or atenolol for infantile haemangioma during infancy, participated in this 2-centre cross-sectional study. The primary endpoint was change in appearance of the infantile haemangioma from pre-treatment to follow-up, using a physician-rated visual analogue scale (VAS). Secondary outcomes were the Patient Observer Scar Assessment Scale (physician- and parent-rated) and a VAS (child-rated), assessing the residual lesion. In total, 103 children (35 treated with propranolol, 68 with atenolol) were analysed. No differences were found between children treated with propranolol and children treated with atenolol on physician-rated VAS (p = 0.10) or any secondary outcomes. Physicians indicated a large aesthetic improve-ment from pre- treatment to follow-up. Physicians, parents and children were positive about the current state of the residual lesion. Minor sequelae were common (86%). These results, in combination with the favourable safety profile of atenolol, should be considered when choosing beta-blocker treatment for infantile haemangioma.

Original languageEnglish
Article numberadv00788
Pages (from-to)adv00788
JournalActa Dermato-Venereologica
Volume102
DOIs
Publication statusPublished - 11 Oct 2022

Bibliographical note

Funding Information:
An unrestricted grant was provided by Pierre Fabre Dermatologie.

Funding Information:
An unrestricted grant was provided by Pierre Fabre Dermatologie. This study was exempt from the Dutch Medical Research Involving Human Subjects Act according to the Institutional Review Boards of the Erasmus MC (MEC-2019-0268) and the UMCU (19-115/C). All parent(s)/guardian(s) provided written informed consent. Netherlands Trial Register, NL7703 https://www.trialregister. nl/trial/7703.

Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.

Fingerprint

Dive into the research topics of 'Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma'. Together they form a unique fingerprint.

Cite this